Gerardo Ferbeyre, a research member at the Institute, and Sebastian Igelmann, a doctoral student in his laboratory and first author of the study, have made a discovery that opens a new avenue for potential cancer therapies. The two scientists published a study in Molecular Cell showing that an enzyme complex called HTC (hydride transfer complex) can inhibit cell aging.
When cells age, a state called “cellular senescence” occurs and cells stop dividing. HTC, composed of three enzymes, may be a potential target for stopping the growth of cancer cells in certain types of cancer, including prostate cancer.
New treatment for prostate cancer approved
13 January 2023
An international study led by Dr. Fred Saad has resulted in the approval of a new treatment for metastatic castration-resistant […]
September 27: Prostate cancer information evening
1 August 2023
The Prostate Cancer Support Group and the CHUM, in collaboration with the Montreal Cancer Institute and the Fondation Virage, invite […]